 Following the review of hepatic adverse events, the FDA has instituted a partial clinical hold impacting the open-label extension OLE phase of Phase 23 GAIN trial of Cortexyme Inc NASDAQ: CRTX evaluating atuzaginstat COR388 in patients with mild to moderate Alzheimers disease. The adverse events were reversible and without any known long-term adverse effects for the participants. 